Recent research presented at AAAAI 2021 Virtual Annual Meeting suggests asthma is not an independent risk factor for severe COVID-19 or hospitalization.
Statistically significant reductions in annual exacerbation rates were seen across baseline eosinophil and exhaled FeNO level and allergy status with telepezumab, in the phase 3 NAVIGATOR trial.
Treatment for severe asthma may be enhanced using an online decision support tool that draws on expert treatment decisions for a wide variety of potential patient scenarios.
Patients with COVID-19 who have asthma share a similar risk of hospitalization with patients with the infection who do not have asthma, according to new research.
AAAAI Virtual Annual Meeting. Among patients with asthma, wearing a mask, regardless of type or duration of use, had no significant effect on oxygen saturation.
Get a first look at key 8 studies to be presented at the upcoming AAAAI 2021 virtual meeting starting this Friday, February 26, 2021.
AAAAI Virtual Annual Meeting. Two-thirds of severe asthma patients dependent upon oral corticosteroids stopped or maximally reduced use, according to the trial data.